SR9009 raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2025-11-21. Anything still debated is marked as such rather than presented as settled.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.
Handling recommendations for SR9009 in a laboratory setting include storing the solid at low temperature, protected from light and moisture. The compound is often dissolved in dimethyl sulfoxide or ethanol for experiments. Solutions should be prepared with appropriate personal protective equipment and disposed of according to local rules. Stability data for long-term storage are limited, so stock solutions are typically kept cold and used within defined periods. Records of preparation date and concentration support reproducibility.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small-molecule nuclear receptor ligand |
| Appearance | Off-white to pale yellow solid | Typical for research-grade powder |
| Solubility class | Soluble in DMSO; low water solubility | Common stock solutions use organic solvent |
| Typical stock solvent | Dimethyl sulfoxide | Used for laboratory assays |
| Common analytical method | HPLC with UV or mass detection | Used for identity and purity checks |
SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
Additionally, while cocaine overdose victims showed a large increase in KORs (doubled) in the NAcc, KOR agonist administration is shown to be effective in decreasing cocaine seeking and self-administration. Furthermore, while cocaine abuse is associated with lowered prolactin response, KOR activation causes a release of prolactin, a hormone known for its important role in learning, neuronal plasticity and myelination. It has also been reported that the KOR system is critical for stress-induced drug-seeking. In animal models, stress has been demonstrated to potentiate cocaine reward behavior in a kappa opioid-dependent manner. These effects are likely caused by stress-induced drug craving that requires activation of the KOR system. Although seemingly paradoxical, it is well known that drug taking results in a change from homeostasis to allostasis. It has been suggested that withdrawal-induced dysphoria or stress-induced dysphoria may act as a driving force by which the individual seeks alleviation via drug taking. The rewarding properties of drug are altered, and it is clear KOR activation following stress modulates the valence of drug to increase its rewarding properties and cause potentiation of reward behavior, or reinstatement to drug seeking. The stress-induced activation of KORs is likely due to multiple signaling mechanisms. The effects of KOR agonism on dopamine systems are well documented, and recent work also implicates the p38 MAPK cascade and pCREB in KOR-dependent behaviors.
MVA-BN (brand names: Imvanex, Imvamune, and Jynneos) is a modified vaccinia Ankara (MVA) vaccine manufactured by Bavarian Nordic by growing MVA in cell culture. Unlike replicating vaccines, MVA-BN is administered by injection via the subcutaneous route and does not result in a vaccine "take." A "take" or "major cutaneous reaction" is a pustular lesion or an area of definite induration or congestion surrounding a central lesion, which can be a scab or an ulcer. MVA-BN can also be administered intradermally to increase the number of available doses. It is safer for immunocompromised patients and those who are at risk from a vaccinia infection. MVA-BN has been approved in the European Union, Canada, and the United States. Clinical trials have found that MVA-BN is safer and just as immunogenic as ACAM2000. This vaccine has also been approved for use against mpox. It received WHO prequalification against smallpox and Mpox in September 2024.
=== Controversy === Based on the statistics presented in earlier discussions, there is controversy with regard to a perceived lack of diversity within the donor sperm pool of many sperm banks. This includes, but is not limited to, height requirements implemented by some sperm banks. As a result, it is alleged that potential sperm recipients often encounter very limited sperm donor pool options. Lack of diversity results in very limited choices especially among ethnic minorities within the United States. Whenever an individual chooses to specify their preferred donor background, the number of available options (sperm donors that meet the particular individual's criteria) can dwindle down to the low single digits. Scott Brown from California Cryobank admitted: "We don't get as many minority applicants as we [would] like." Even after numerous attempts to reach out to numerous ethnic communities, the response can be nearly nonexistent. At the California Cryoback, Brown mentions that one out of 100 would be able to become final sperm donor while Ottey from the Fairfax Cryobank mentions one out of 200 would be able to become ultimate sperm donors. In addition, locations of the California Cryobank are in Los Angeles, Los Altos, California; mid-Manhattan, and Cambridge Massachusetts. These locations are known to have a population with higher socioeconomic latitude and being more likely to afford the services.
Pancreatic cancers, particularly the most common type, pancreatic adenocarcinoma, remain very difficult to treat, and are mostly diagnosed only at a stage that is too late for surgery, which is the only curative treatment. Pancreatic cancer is rare in people younger than 40 and the median age of diagnosis is 71. Risk factors include chronic pancreatitis, older age, smoking, obesity, diabetes, and certain rare genetic conditions including multiple endocrine neoplasia type 1, hereditary nonpolyposis colon cancer and dysplastic nevus syndrome among others. About 25% of cases are attributable to tobacco smoking, while 5–10% of cases are linked to inherited genes. Pancreatic adenocarcinoma is the most common form of pancreatic cancer and is a cancer arising from the exocrine digestive part of the pancreas. Most occur in the head of the pancreas. Symptoms tend to arise late in the course of the cancer, when it causes abdominal pain, weight loss, or yellowing of the skin (jaundice). Jaundice occurs when the cancer blocks the outflow of bile. Other less common symptoms include nausea, vomiting, pancreatitis, diabetes, or recurrent venous thrombosis. Pancreatic cancer is usually diagnosed by medical imaging in the form of an ultrasound or CT scan with contrast enhancement. An endoscopic ultrasound may be used if a tumour is being considered for surgical removal, and biopsy guided by ERCP or ultrasound can be used to confirm an uncertain diagnosis. Because of the late development of symptoms, most cancer presents at an advanced stage.
Sources: en.wikipedia.org
Iceland, on the contrary, has a rather low prevalence of 1 per 100,000, despite the fact that Icelanders as a people are descended from the early Germanic tribes of Scandinavia which also gave rise to the Swedes; all cases with the exception of one going back nearly two centuries having derived from the offspring of a couple living early in the 19th century. Finland, as well, has a low incidence of only 2.2 per 100,000 people. Until the discovery of a genetic test, statistics could only include clinical diagnosis based on physical symptoms and a family history of HD, excluding those who died of other causes before diagnosis. These cases can now be included in statistics; and, as the test becomes more widely available, estimates of the prevalence and incidence of the disorder are likely to increase.
Indeed, according to Williams, the goal of this analysis is to understand how suffering arises for sentient beings through an impersonal law and thus how it can also be brought to an end by reversing its causes. Understood in this way, dependent origination has no place for a creator God nor the ontological Vedic concept called universal Self (Brahman) nor any other 'transcendent creative principle'. In this worldview, there is no 'first cause' from which all beings arose, instead, every thing arises in dependence on something else. Though Eviatar Shulman sees dependent origination as mainly being concerned with mental processes, he also states that it "possessed important ontological implications" which "suggest that rather than things being conditioned by other things, they are actually conditioned by consciousness." This is implied by the fact that form (rūpa) is said to be conditioned by consciousness and willed activities (saṇkhara) as well as by how grasping is said to condition existence (bhava). For Shulman, "these forms of conditioning undermine the realistic ontology normally attributed to early Buddhism" and furthermore "suggest that the mind has power over objects beyond what we normally believe" as well as implying that "ontology is secondary to experience." While some scholars have argued that the Buddha put aside all metaphysical questions, Noa Ronkin argues that, while he rejected certain metaphysical questions, he was not an anti-metaphysician: nothing in the texts suggests that metaphysical questions are completely meaningless.
A 2017 systematic review and meta-analysis of 57 randomized controlled trials (RCTs) found that clonidine improved postoperative pain control. In a subset of trials reporting detailed postoperative analgesia outcomes, clonidine delayed the time until patients required additional pain medication and reduced cumulative postoperative analgesic consumption over the first 24 hours by ~24%. The same review reported that clonidine reduced the incidence of postoperative nausea and vomiting compared with placebo. Meta-analyses of α2 adrenoreceptor agonists (i.e., clonidine and dexmedetomidine) likewise report small to moderate reductions in postoperative pain intensity and opioid consumption during the first postoperative day, consistent with an opioid-sparing effect, but are limited by substantial statistical heterogeneity. In one meta-analysis of clonidine RCTs, overall adverse event rates did not differ significantly between clonidine and placebo. However, that same paper noted that a large included trial reported a higher incidence of hypotension and non-fatal cardiac arrest with clonidine, and that the available data were insufficient to rule out uncommon but serious hemodynamic complications.
=== Cancer === Heejin et al. showed that trimebutine is effective at stopping ovarian cancer cells from growing in vitro. This effect is believed to be exerted through G0/G1 phase switch arrest, voltage-gated calcium channels and calcium-activated potassium channels inhibition and suppressing Wnt, Notch and Hedgehog pathways. Yi-pu Fan et al. found that trimebutine can inhibit glioma and glioblastoma cells from proliferating by promoting apoptosis and downregulation of Bcl-2, thereby upregulating Bax pro-apoptotic factor.
The Earldom of Carlisle was partitioned into baronies. When the County of Cumberland was created, the baronies were subdivided as wards, a county sub-division also used in Durham, Northumberland and Westmorland. These originated as military subdivisions used to organise the male inhabitants for the county's defence from Scottish troop incursions. Each ward was composed of a number of parishes, areas originally formed for ecclesiastical administration. In common with other northern England counties, many ancient parishes in Cumberland were very large, often consisting of a number of distinct townships and hamlets. Many of these ancient parishes eventually became civil parishes and form the lowest level of local government.
Sources: en.wikipedia.org
== Murders and assaults == While she was a nurse at Caressant Care, Wettlaufer began injecting some of the patients she cared for with insulin. In some cases, the amount was not enough to kill the patient; she was charged with, and confessed to, aggravated assault or attempted murder for those cases. Wettlaufer's first assaults occurred sometime between June 25 and December 31, 2007. She confessed that she injected sisters Clotilde Adriano (age 87) and Albina Demedeiros (88) with insulin. While they later died, their deaths were not attributed to Wettlaufer. She confessed to two counts of aggravated assault. The first case in which Wettlaufer injected a patient with enough insulin to directly cause death was on August 11, 2007, when she murdered James Silcox (84), a World War II veteran and father of six. From 2007 to March 2014, Wettlaufer also murdered the following patients at Caressant Care:
The courts give the EU a wide discretion to implement policy, so judicial review is possible only if agricultural measures are 'manifestly inappropriate'. EU law does not yet have a systematic plan or subsidies to rewild depleted environments, and to move to complete clean energy infrastructure.
==== March 2008 hepatitis ==== In March and April 2008, the Community Epidemiology Branch of the San Diego County Health and Human Services Agency traced a hepatitis A outbreak in San Diego County to a single Chipotle restaurant located in La Mesa, California, in which 22 customers were infected with the virus.
In another European study, 5 years after treatment for neuroborreliosis lingering symptoms were less common among children (15%) than adults (30%), and in the latter were less common among those treated within 30 days of the first symptom (16%) than among those treated later (39%); among those with lingering symptoms, 54% had daily activities restricted and 19% were on sick leave or incapacitated. Some data suggest that about 90% of Lyme facial palsies treated with antibiotics recover fully a median of 24 days after appearing and most of the rest recover with only mild abnormality. However, in Europe 41% of people treated for facial palsy had other lingering symptoms at followup up to 6 months later, including 28% with numbness or altered sensation and 14% with fatigue or concentration problems. Palsies in both sides of the face are associated with worse and longer time to recovery. Historical data suggests that untreated people with facial palsies recover at nearly the same rate, but 88% subsequently have Lyme arthritis. Other research shows that synkinesis (involuntary movement of a facial muscle when another one is voluntarily moved) can become evident only 6–12 months after facial palsy appears to be resolved, as damaged nerves regrow and sometimes connect to incorrect muscles. Synkinesis is associated with corticosteroid use. In longer-term follow-up, 16–23% of Lyme facial palsies do not fully recover.
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that acts on REV-ERB nuclear receptors. It is not approved for human use and is sold only as a research chemical. Its effects have been studied mainly in cells and rodents.
It binds REV-ERB alpha and REV-ERB beta and changes the expression of genes tied to metabolism and circadian rhythm. These changes can affect mitochondria and energy use in animal models. The exact chain from receptor binding to physiological outcome is still being mapped.
No reliable human trials show that SR9009 improves athletic performance. Some rodent studies report endurance changes, but these results are not proof of human benefit. Its use in sport is prohibited, and quality and safety data are lacking.
Its legal status depends on the country and intended use. It is not an approved medicine in major jurisdictions. In sport, it is prohibited by anti-doping rules.